CompletedNCT00088621
One-year safety of lurasidone for schizophrenia
About this title
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
Read the official source — NCT00088621Medication studyAges 18–64United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJuly 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 61
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00088621
- Official title
Show the full official title
An Open-Label, Multicenter, Twelve-Month Study of Safety and Tolerability in the Treatment of Schizophrenia
Get this study by email
Recruitment & locations
CompletedBirmingham · Little Rock · Cerritos
16 more locations
- Garden Grove
- La Mesa
- San Diego
- Upland
- Washington D.C.
- Fort Lauderdale
- North Miami
- Tampa
- Hoffman Estates
- Las Vegas
- Clementon
- Philadelphia
- Austin
- Bellaire
- DeSoto
- Falls Church
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone 80mg tablet.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
